Arecor Therapeutics (LSE:AREC) Long-Term Capital Lease Obligation : £0.22 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Arecor Therapeutics Long-Term Capital Lease Obligation?

Arecor Therapeutics's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was £0.22 Mil.

Arecor Therapeutics's quarterly Long-Term Capital Lease Obligation declined from Dec. 2022 (£0.09 Mil) to Jun. 2023 (£0.05 Mil) but then increased from Jun. 2023 (£0.05 Mil) to Dec. 2023 (£0.22 Mil).

Arecor Therapeutics's annual Long-Term Capital Lease Obligation declined from Dec. 2021 (£0.11 Mil) to Dec. 2022 (£0.09 Mil) but then increased from Dec. 2022 (£0.09 Mil) to Dec. 2023 (£0.22 Mil).

Arecor Therapeutics Long-Term Capital Lease Obligation Historical Data

The historical data trend for Arecor Therapeutics's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arecor Therapeutics Long-Term Capital Lease Obligation Chart

Arecor Therapeutics Annual Data

Trend

May17

May18

May19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.13

0.19

0.11

0.09

0.22

Arecor Therapeutics Semi-Annual Data
	May18	May19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial					0.11	0.04	0.09	0.05	0.22

Arecor Therapeutics (LSE:AREC) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Arecor Therapeutics Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Arecor Therapeutics's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Arecor Therapeutics (LSE:AREC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arecor Therapeutics PLC (LSE:AREC) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

6UI:Germany

Address

Chesterford Research Park, Little Chesterford, Saffron Walden, GBR, CB10 1XL

Website

https://www.arecor.com

Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying an innovative proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Switzerland, the Rest of Europe, the USA, India, and the Rest of the World, out of which the majority is from the UK.